Outcome analysis in clinical trial design for acute stroke: Physicians' attitudes and choices

Cerebrovascular Diseases

Volumn 26, Issue 2, 2008, Pages 156-162

  Savitz, Sean I ^a   Benatar, Michael ^b   Saver, Jeffrey L ^c   Fisher, Marc ^d  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Acute stroke; Imaging evaluation; Outcome analysis, physician's view

Indexed keywords

DISUFENTON SODIUM; NEUROPROTECTIVE AGENT;

ARTICLE; CEREBROVASCULAR ACCIDENT; INTERNET; MEDICAL SPECIALIST; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; NEUROPROTECTION; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RANKIN SCALE;

ATTITUDE OF HEALTH PERSONNEL; CHOICE BEHAVIOR; CLINICAL TRIALS AS TOPIC; COMPREHENSION; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOSPITALS, UNIVERSITY; HUMANS; INTERNET; MALE; NEUROPROTECTIVE AGENTS; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME; UNITED STATES;

EID: 49949094628     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000139663     Document Type: Article

References (17)

1. Kidwell CS, Liebeskind DS, Starkman S, Saver JL: Trends in acute ischemic stroke trials through the 20th century. Stroke 2001;32:1349-1359.
2. Adams H: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005;36:880-890.
3. Ehrenreich H, Hasselblatt M, Dembowski C, et al: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
4. Lees KR, Zivin JA, Ashwood T, et al: NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600.
5. Saver JL: Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004;61:1066-1070.
6. Gray LJ BP, Collier T: Optimizing the statistical analysis of functional outcome in stroke clinical trials. Cerebrovasc Dis 2005;19:116.
7. Lin IF, Schaeffer N: Using survey participants to estimate the impact of nonparticipation. Public Opin Q 1995;59:236-258.
8. Kaste M: Use of animal models has not contributed to development of acute stroke therapies: pro. Stroke 2005;36:2323-2324.
9. Fisher M: The ischemic penumbra: a new opportunity for neuroprotection. Cerebrovasc Dis 2006;21(suppl 2):64-70.
10. Furlan AJ, Eyding D, Albers GW, et al: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 h after stroke onset. Stroke 2006;37:1227-1231.
11. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg M, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP, DEFUSE Investigators: Magnetic resonance imaging profiles predict clinical response to early reperfusion: the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Ann Neurol 2006;60:508-517.
12. Marler J: Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
13. Fisher M: Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001;32:1598-1606.
14. Adams H: Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998;279:1265-1272.
15. Dobkin BH: Clinical practice: rehabilitation after stroke. N Engl J Med 2005;352:1677-1684.
16. Grotta JC: Acute stroke therapy at the millennium: consummating the marriage between the laboratory and bedside. The Feinberg lecture. Stroke 1999;30:1722-1728.
17. Samsa GP, Matchar DB:. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke 2001;32:669-674.